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Introduction
Chronic migraine (CM) is a prevalent and disabling neuro-
logical disorder. OnabotulinumtoxinA is the only approved
therapy specifically for CM. The results from randomized
controlled trials often reflect, but rarely define, the spec-
trum of patient outcomes. The proportion of patients
highly responsive to a therapy is an important endpoint
and guide for clinicians and patients.
Objective
To determine the proportion of patients who are highly
responsive (75% responder rate) to therapy in 2 double-
blind, placebo-controlled, parallel studies (PREEMPT 1
& 2).
Methods
PREEMPT (two phase 3 studies: 24-week, double-blind,
placebo-controlled, parallel-group phase, followed by
32-week, open-label phase) evaluated onabotulinumtoxinA
for prophylaxis of headaches in CM (15 days/month with
headache lasting 4 hours/day or longer). Patients were
randomized (1:1) to onabotulinumtoxinA (155-195U) or
placebo every 12 weeks. The proportions of patients with
75% decrease from baseline in frequency of headache days,
headache episodes, migraine days, migraine episodes,
moderate/severe headache days, and total cumulative
hours of headache on headache days were analyzed.
Results
Pooled analyses (onabotulinumtoxinA n=688, placebo
n=696) demonstrated a statistically significant between-
group difference favoring onabotulinumtoxinA in the
proportion of patients who had a 75% reduction from
baseline in headache days at Week 24 (22.8% onabotuli-
numtoxinA, 15.5% placebo; p=0.002). For all above head-
ache symptom measures, a significantly greater proportion
of onabotulinumtoxinA-treated than placebo-treated
patients had 75% decreases from baseline.
Conclusions
PREEMPT supports the efficacy and tolerability of onabo-
tulinumtoxinA for the prophylaxis of headache in adults
with CM.[1] These data demonstrate that onabotulinum-
toxinA treatment results in a significant 75% reduction in
multiple headache symptom measures and highly substan-
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